Messenger RNA (mRNA)

Subscribe to Selected New Research on Messenger RNA

47994 relevant articles (654 outcomes, 4560 trials/studies) found for this Bio-Agent

Description: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.

Also Known As:

mRNA; Poly(A) Tail; RNA, Messenger; Non-Polyadenylated mRNA; Poly(A) RNA; Polyadenylated mRNA; Non Polyadenylated mRNA; Polyadenylated Messenger RNA; Polyadenylated RNA; RNA, Polyadenylated Messenger; mRNA, Non Polyadenylated; Messenger RNA, Polyadenylated; Poly(A)+ RNA; Poly(A)+ mRNA; RNA, Messenger, Polyadenylated; RNA, Polyadenylated; mRNA, Non-Polyadenylated; mRNA, Polyadenylated

Relationship Network

Bio-Agent Context: Research Results

Nucleic Acids, Nucleotides, and Nucleosides: 1

RNA Splice Sites: 299

Untranslated Regions: 120

Stored Messenger RNA: 4

mitochondrial messenger RNA: 3

adapt73: 1

non-coding transcript abundantly expressed in brain

oligo(U+)RNA

RNA Caps

RNA HYMAI

Experts

1.	Taguchi, Tetsuya: 15 articles (08/2007 - 01/2002)
2.	Tamaki, Yasuhiro: 15 articles (08/2007 - 01/2002)
3.	Noguchi, Shinzaburo: 15 articles (08/2007 - 01/2002)
4.	Miyoshi, Yasuo: 15 articles (08/2007 - 01/2002)
5.	Schneider, Paul M: 12 articles (03/2008 - 02/2002)
6.	Danenberg, Kathleen D: 11 articles (12/2008 - 02/2002)
7.	Danenberg, Peter V: 11 articles (12/2008 - 02/2002)
8.	Metzger, Ralf: 11 articles (09/2008 - 02/2002)
9.	Brabender, Jan: 11 articles (09/2007 - 02/2002)
10.	Sasaki, H: 11 articles (01/2005 - 09/2000)

Related Diseases

1.	Neoplasms (Cancer) 03/01/2006 - "RESULTS: Although the NORE1A mRNA levels of the majority of the tumors were similar to those in the normal controls, the cases harboring a PAX8-PPARgamma translocation (n = 6) exhibited dramatically reduced NORE1A expression (P < 0.001)" 05/01/2002 - "Of 182 unifocal primary HCCs, ANXA10 mRNA was dramatically reduced in 121 (66%), and the down-regulation correlated with p53 mutation (P = 0.024), early intrahepatic tumor recurrence (P = 0.0007), and lower 4-year survival (P = 0.0014)" 03/01/2000 - "These results suggest that the use of a c-myc mRNA cleaving enzyme could be most effective in tumor cells that are highly proliferative and constitutively express high levels of c-myc." 09/15/1997 - "Interestingly, purified T and B cells isolated from immunocompromised tumor-bearing mice displayed a marked decrease in the transcription activators STAT5a and -b at the protein level and to a lesser extent at the mRNA level" 03/01/2006 - "In summary, we were able to detect Rex-1 mRNA and protein expression in over 90% of normal renal parenchymal specimens and we observed a significant reduction in REX1 expression in renal tumor specimens of all histologic subtypes." Order ALL the reference details at left...
2.	Infection 05/16/2003 - "Thus, M1GS ribozyme is highly effective in inhibiting HCMV growth by targeting the PR mRNA and may represent a novel class of general gene-targeting agents for the studies and treatment of infections caused by human viruses, including HCMV." 05/01/2007 - "When CD83 surface expression was inhibited by interference with the messenger RNA export or by infection with certain viruses, DCs showed a dramatically reduced capability to induce T cell proliferation" 07/30/2002 - "RESULTS: Our results showed that infection of MCF-7 cells with the adenovirus carrying a ribozyme targeted against the M6P/IGF2R mRNA dramatically reduced the level of transcripts and the functional activity of M6P/IGF2R in these cells" 12/07/2003 - "A significant reduction of IFN-beta mRNA but not PBGD mRNA was demonstrated 5 h after CVB3 infection, indicating a specific inhibition of IFN-beta expression by CVB3 on the mRNA level, in addition to previously reported effects on the translation/post-translation level" 01/01/2003 - "However, there was a significant reduction in IFN-gamma mRNA levels when cells were stimulated with a multiplicity of infection of greater than 1 virulent M" Order ALL the reference details at left...
3.	Ischemia 05/15/2006 - "GLUT4 mRNA and protein levels were dramatically reduced by chronic ischemia, regardless of whether the animals were exercise-trained or not" 03/06/2007 - "Global ischemia induces a marked decrease in MOR-1 mRNA and protein expression that is specific to the selectively vulnerable area CA1, as assessed by quantitative real-time RT-PCR, Western blotting, and ChIP" 02/01/2002 - "In additional studies, nondiabetic and diabetic hearts, without the ischemia/reperfusion protocol, were subjected to electrical fibrillation, and a significant reduction in COXBIII and ATPS6 mRNA signal intensity was observed indicating that VF contributes to the down-regulation of these genes" 01/01/2005 - "A significant reduction in the expression of TR-PM7 mRNA was found in EA treated group in contrast to ischemia/reperfusion group (P<0.05)" 08/01/2000 - "Protection against myocardial dysfunction induced by global ischemia-reperfusion by antisense-oligodeoxynucleotides directed at beta(1)-adrenoceptor mRNA." Order ALL the reference details at left...
4.	Fibrosis (Cirrhosis) 10/01/2008 - "Moreover, it dramatically reduced hepatic inflammatory changes and fibrosis concomitantly with marked reductions in the mRNA levels for inflammatory cytokine, chemokine, and profibrogenic genes" 08/01/2008 - "In acute study using a single drug injection, we observed a rapid transient increase of ALT and mRNA levels of KLF5 followed by increases in fibrosis-related genes" 12/01/2005 - "METHODS: We used real-time quantitative RT PCR to study the messenger RNA expression of 240 selected genes in 2 pools of liver specimens according to the stages of fibrosis (Metavir score; mild fibrosis = F1 and septal fibrosis = F2)" 01/01/2002 - "The purpose of the present study was to assess the correlation that likely exists among increased portal pressure (Pp), portal blood flow quantity (Qp) and ETA and ETB receptor mRNA expression in human cirrhosis" 01/01/2000 - "PDGF-B mRNA increase up to day 15, marking the onset of fibrosis, and decreases thereafter, whereas the expression of the PDGF-Rbeta mRNA remains elevated more than threefold over the entire study period" Order ALL the reference details at left...
5.	Inflammation 02/01/2006 - "CONCLUSIONS: The combination of topical treatment of NaB and 5-ASA was effective for relieving and repairing colonic inflammation and the effects were related to stimulation of TFF3 mRNA expression and down-regulation of IL1beta production and NFkappaB expression." 06/01/2000 - "NOSII mRNA expression decreases in asthmatics receiving inhaled corticosteroid, treatment effective in reducing inflammation in asthmatic airways" 06/01/2008 - "BUD and DXM can up-regulate the expression of HO-1 protein and mRNA, thus providing protective effects against the airway inflammation in asthmatic rats." 03/14/2008 - "RESULTS: Increased expression of Fox P3 mRNA was found in all five patients who responded to cytapheresis with remission of clinical symptoms, mucosal inflammation and cutaneous lesions, and an increased frequency of circulating Tregs was found in four patients" 02/01/1991 - "This indicated that there was no preferential accumulation of mRNA specifying a particular isotype and no preferential synthesis or clearance of a particular isotype during chronic inflammation and the early stages of amyloidogenesis in either strain" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
2.	Messenger RNA (mRNA)
3.	Transforming Growth Factor beta1 (TGF beta 1)
4.	Cytokines
5.	DNA (Deoxyribonucleic Acid)
6.	RNA (Ribonucleic Acid)
7.	Proteins (Proteins, Gene)
8.	Collagen Type I (Type I Collagen)
9.	Interleukin-6 (Interleukin 6)
10.	Interleukin-10 (Interleukin 10)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Transplants (Transplant)
3.	Immunotherapy
4.	Bone Marrow Transplantation (Transplantation, Bone Marrow)
5.	Aftercare (After-Treatment)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 18530 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>